Compare Archer Aviation Inc (ACHR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer Aviation Inc vs Merck & Co., Inc. — how do they compare? Archer Aviation Inc trades at $4.88 (market cap $3.76B), while Merck & Co., Inc. trades at $126.5 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 84.6× Archer Aviation Inc's market cap, and Merck & Co., Inc. pays a 2.64% dividend while Archer Aviation Inc pays none. Which is the better fit depends on your goals.
| ACHR | MRK | |
|---|---|---|
Market Cap | $3.76B | $318.26B |
Sector | Industrials | Health |
52-Week High | $13.64 | $129.52 |
52-Week Low | $4.68 | $77.60 |
Enterprise Value | $2.11B | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $5.37, up 7.83% with a bearish technical signal despite recent momentum. The company shows severe financial strain with -$618.2M net income on minimal $300K revenue in 2025, though analyst sentiment remains optimistic with 78% buy ratings. Recent news highlights progress toward FAA certification for its Midnight eVTOL aircraft, with commercialization targeted for 2028 and a $6B order book providing long-term potential.
The stock presents high-risk speculative potential with significant execution hurdles. While regulatory progress and major partnerships with United Airlines and Stellantis support the bullish case, persistent cash burn and negative margins require substantial capital raises. Investors face binary outcomes dependent on successful certification and commercial deployment timelines against intense competition in the emerging eVTOL market.
Merck (MRK) trades at $125.84, down 0.74% on the day, with a bullish technical outlook and strong institutional support. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives amid positive analyst sentiment.
The stock offers upside to the $139.33 consensus price target, supported by solid profitability and cash flow, but faces risks from rising debt levels and competitive pressures in the pharma sector. Investors should weigh the growth potential from M&A against execution risks and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer Aviation Inc
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
